SUMMARY: The Israeli military issued new evacuation orders for central Gaza, particularly around Deir al-Balah, restricting access to southern cities Rafah and Khan Younis. This marks a rare ground operation area amid ongoing, stalled ceasefire talks with Hamas in Qatar. Prime Minister Netanyahu says increased military pressure aims to push Hamas to negotiate. International aid groups in the evacuation zone have not commented. The military urged residents to move to a designated humanitarian tent camp, Muwasi. Gaza faces a catastrophic humanitarian crisis after Hamas’s Oct. 7 attack and subsequent Israeli offensive, which has caused over 58,000 Palestinian deaths. Families of hostages and Israeli protesters demand an end to the conflict.

Read the full article

The post Israel orders evacuations in central Gaza as ceasefire talks stall and military offensive widens appeared first on www.clickorlando.com

SUMMARY: The Trump administration imposed new restrictions on flights from Mexico, citing violations of a U.S.-Mexico aviation agreement. Transportation Secretary Sean Duffy criticized Mexico for forcing airlines to use a less accessible airport, claiming it favored domestic carriers. In response, Mexican airlines must now seek U.S. approval for all flights. The move also threatens the Delta-Aeromexico partnership, which has existed since 2016 and supports \$800 million in annual savings. Delta warned the breakup would hurt consumers and jobs. The order to end the partnership won’t take effect until October, giving both airlines time to contest the decision.

Read the full article

The post Trump administration imposes limits on Mexican flights and threatens Delta alliance in trade dispute appeared first on www.news4jax.com

SUMMARY: Sarepta Therapeutics refused the FDA’s request to halt shipments of its gene therapy Elevidys after three patient deaths linked to liver injury. The FDA’s unusual move followed concerns over safety, particularly for older Duchenne muscular dystrophy patients. Elevidys, the first U.S.-approved gene therapy for this fatal muscle-wasting disease, received accelerated approval despite initial doubts about effectiveness. Sarepta halted sales for older patients but plans to keep the drug available for younger ones. The company confirmed a third death in an experimental trial, prompting the FDA to pause that study. Sarepta faces criticism over transparency and has recently cut 500 jobs amid plummeting stock value.

Read the full article

The post Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths appeared first on www.clickorlando.com